Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
07:55am, Saturday, 02'nd May 2026
The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
03:35pm, Thursday, 30'th Apr 2026
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
06:27pm, Wednesday, 29'th Apr 2026
There's power in the company's No. 1 molecule.
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
03:01pm, Wednesday, 29'th Apr 2026
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
08:46am, Wednesday, 29'th Apr 2026
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.81. This compares to a loss of $1.55 per share a year ago.
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
06:30am, Wednesday, 29'th Apr 2026
Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025 Strong initial U.S. commerci
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
05:36am, Friday, 24'th Apr 2026
A rival company's trial results had a negative impact on Agios' stock this week.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
11:01am, Wednesday, 22'nd Apr 2026
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
10:36am, Tuesday, 21'st Apr 2026
AGIO shares plunge after Novo Nordisk's strong sickle cell data raised doubts about mitapivat's competitiveness and approval prospects.
Here's Why Agios Pharmaceuticals Crashed 23% Today
12:19pm, Monday, 20'th Apr 2026
The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.
SG Americas Securities LLC Increases Position in Agios Pharmaceuticals, Inc. $AGIO
05:18am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 68.0% during the fourth quarter, according to the company in its most recent disclosure with the Securit
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
07:00am, Monday, 06'th Apr 2026
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wi
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
12:16pm, Wednesday, 01'st Apr 2026
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
09:00am, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concern
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
06:50am, Wednesday, 01'st Apr 2026
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mo
